Physician profile
Katherine A Kosche
NPI 1003823972
$6,233.16
in general payments reported to CMS, 2019-2025
30 companies · $884 in 2025
The $884 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $1,421 · 2021: $1,207 · 2022: $659 · 2023: $578 · 2024: $564 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.88 | 2019-2025 | |
| Janssen Biotech, INC. | $1,036.74 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $665.42 | 2019-2023 | Xifaxan |
| Pfizer INC. | $466.44 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $442.25 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $404.71 | 2019-2025 | Entyvio |
| Braintree Laboratories, INC. | $264.70 | 2019-2021 | |
| Madrigal Pharmaceuticals | $255.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $212.42 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $157.73 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $151.75 | 2020-2024 | |
| Redhill Biopharma INC. | $148.27 | 2020-2021 | |
| Qol Medical, LLC | $125.07 | 2020-2025 | Sucraid |
| Daiichi Sankyo INC. | $88.83 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $85.48 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $78.37 | 2024-2025 | Vegzelma |
| Allergan, INC. | $75.05 | 2019-2020 | |
| Gilead Sciences, INC. | $62.87 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $49.31 | 2021-2022 | |
| Olympus America INC. | $47.74 | 2023 | Endoclot Phs |
| Celgene Corporation | $47.26 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $39.01 | 2024-2025 | Voquezna |
| Amgen INC. | $38.71 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $32.47 | 2025 | Iqirvo |
| Alexion Pharmaceuticals, INC. | $30.13 | 2019 | |
| Davol INC. | $27.24 | 2020 | |
| Ardelyx, INC. | $24.10 | 2024 | Ibsrela |
| Boston Scientific Corporation | $18.17 | 2019 | |
| Lilly USA, LLC | $16.91 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $16.05 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Kosche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.